KYMR vs QGEN: stock comparison and AI forecast
Kymera Therapeutics, Inc. (KYMR) and Qiagen N.V. (QGEN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KYMR Kymera Therapeutics, Inc.
- Price
- $127.51 +52.5% · 6M
- Market Cap
- $10.60B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
QGEN Qiagen N.V.
- Price
- $50.35 +48.3% · 6M
- Market Cap
- $10.92B
- P/E Ratio
- 35.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- KYMR and QGEN have similar market capitalizations ($10.60B and $10.92B).
- Over the last six months KYMR returned +52.5% and QGEN +48.3%.
- QGEN turns 15.6% of its revenue into net income, against -514.8% for KYMR.
- QGEN carries 0.66 times debt per unit of equity, against 0.09 times for KYMR.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KYMR | QGEN |
|---|---|---|
| Market Cap | $10.60B | $10.92B |
| P/E Ratio | – | 35.71x |
| P/B Ratio | 6.57x | 2.89x |
| EPS | $-3.74 | $1.41 |
| Book Value/Share | $19.42 | $17.42 |
| Revenue/Share | $0.82 | – |
| FCF/Share | $-3.47 | – |
Profitability & Margins
| Metric | KYMR | QGEN |
|---|---|---|
| ROE | -21.6% | 8.4% |
| ROA | -19.8% | 5.1% |
| ROIC | -24.1% | 6.5% |
| Gross Margin | 0.0% | 59.8% |
| Operating Margin | -596.6% | 18.4% |
| Net Margin | -514.8% | 15.6% |
| EBT Margin | -540.5% | 19.0% |
| Tax Rate | – | 18.1% |
Financial Health
| Metric | KYMR | QGEN |
|---|---|---|
| Current Ratio | 11.13x | 3.90x |
| Quick Ratio | – | 3.31x |
| D/E Ratio | 0.09x | 0.66x |
| Financial Leverage | 1.09x | 1.66x |
| Interest Coverage | -3200.7x | 15.9x |
| Working Capital | $909M | $1.48B |
Cash Flow
| Metric | KYMR | QGEN |
|---|---|---|
| Operating Cash Flow | -$288M | $626M |
| Free Cash Flow | -$289M | – |
| Capital Spending | -$1M | – |
| OCF Growth YoY | – | 40.0% |
| FCF/Sales | -425.6% | – |
| CapEx/Sales | 2.0% | – |
Operational Efficiency
| Metric | KYMR | QGEN |
|---|---|---|
| Asset Turnover | 0.04x | – |
| Inventory Turnover | – | 2.7x |
| Fixed Assets Turnover | 1.8x | – |
| Days Inventory | – | 134 days |
| Payables Period | 64 days | 32 days |
Income Statement
| Metric | KYMR | QGEN |
|---|---|---|
| Total Revenue | $68M | – |
| Operating Income | -$405M | $376M |
| Net Income | -$349M | $318M |
| R&D Expense | $430M | $192M |
| SG&A Expense | – | $678M |
| Cost of Goods Sold | $68M | $822M |
Dividend & Shareholder Information
| Metric | KYMR | QGEN |
|---|---|---|
| Shares Outstanding | 83M | 217M |
| EPS Growth | – | 28.5% |
KYMR vs QGEN: stock comparison and AI forecast
Which is bigger, KYMR or QGEN?
KYMR and QGEN have similar market capitalizations ($10.60B and $10.92B).
Which stock performed better over the last six months, KYMR or QGEN?
Over the last six months KYMR returned +52.5% and QGEN +48.3%.
Which one does Intratio's AI model rank higher, KYMR or QGEN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.